Company news
Formycon Ag (XETR:FYB) news
Formycon Ag news releases on 6ix. Latest, Oct 6, 2026: Formycon Optimizes Biosimilar Development with AI-Powered Technologies: Digital Solutions Enhance…
Press releases & updates
Formycon Optimizes Biosimilar Development with AI-Powered Technologies: Digital Solutions Enhance Development Efficiency as Part of the FYB4GROWTH Strategy
October 6, 2026
Formycon sets Benchmark in Biosimilar Development: Scientific Foundation of the innovative Development Program for FYB206 published in the Journal BioDrugs
September 22, 2026
Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year
August 12, 2026
Formycon invites to conference call on 2026 half-year results and announces participation in international investor conferences
August 5, 2026
Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars
July 14, 2026
Formycon AG Reports Results of Annual General Meeting 2026
June 10, 2026
Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026
May 28, 2026
Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
May 22, 2026
Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences
May 21, 2026
Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive® and Baiama® are now available in the European Union
May 19, 2026
Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
April 22, 2026
Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026
April 20, 2026
Formycon : announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements
April 15, 2026
Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
March 19, 2026
Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
March 18, 2026
Formycon AG publishes preliminary figures for the 2025 fiscal year
March 4, 2026
Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
February 25, 2026
Formycon : Lotus Pharmaceutical becomes commercialization partner for Formycon’s Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
February 11, 2026
Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
December 23, 2025
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
December 9, 2025
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
December 4, 2025
Formycon Announces New Dupilumab Biosimilar Candidate
November 28, 2025
NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
November 24, 2025
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
October 21, 2025
Formycon Invites to Conference Call on 2025 Half-year Results and Announces Participation in International Investor Conferences in the 3rd Quarter of 2025
July 30, 2025
Formycon Successfully Completes Patient Enrollment for the Clinical Development of Its Keytruda(R) Biosimilar Candidate FYB206
July 10, 2025
Ordinary Annual General Meeting of Formycon AG Approves all Proposed Resolutions by Large Majorities
June 18, 2025
Fresenius Kabi to announce the commercial launch of Otulfi™*, an approved Ustekinumab Biosimilar in Canada
May 27, 2025